Singapore Pharmaceutical Licensing

Singapore has a single national regulatory system; no pharmaceutical business licensing system divided into federal and state/provincial levels was identified. HSA issues licences by activity: retail pharmacies supplying POM/P, and the import, wholesale and manufacture of therapeutic products are subject to a pharmacy licence, TPIL, TPWL and TPML respectively. Before applying, distinguish the retail, storage, import, manufacturing and online supply processes.

HSA requires businesses to submit the relevant applications through PRISM and have a CRIS company account. Certain special access routes also require the company to be registered with ACRA. This guide has not exhaustively verified general company incorporation, ownership or foreign investment entry rules, and therefore does not present company form, minimum capital, foreign ownership proportions or shareholding arrangements as uniform conditions for medicines licensing.

— Scope: therapeutic products for human use; veterinary supply, active ingredients, laboratory reagents and similar items may fall within different boundaries.

— Not automatically included: product registration, individual pharmacist registration/practising certificates, approval for each import batch, controlled medicines licences and general corporate compliance.

HSA oversees therapeutic product registration, dealer licensing and pharmacy licensing. The legal framework includes the Health Products Act 2007, the Health Products (Therapeutic Products) Regulations 2016 and the Health Products (Licensing of Retail Pharmacies) Regulations. Retail pharmacies, wholesalers and manufacturers are all subject to HSA’s audit and enforcement framework.

Individual pharmacist qualifications are dealt with under the SPC system. Even if a business’s HSA licence is approved, the proposed PIC or an RP legally required to be a pharmacist should separately maintain SPC registration and a valid practising certificate. The 2 systems cannot substitute for each other.

— HSA: business and premises/activity licensing, product registration and GDP/GMP audits.

— SPC: individual pharmacist registration and qualifications to practise.

— Singapore Statutes Online: the official portal for consulting current legislation.

Retail pharmacies supplying POM or P must obtain an HSA pharmacy licence. A licensed pharmacy is controlled and managed by the PIC named on its licence. The PIC should be a qualified pharmacist who is registered, holds a valid practising certificate and is in active practice. The verified HSA pages do not prescribe a general numerical requirement for a particular proportion of pharmacists to be present throughout all opening hours, so no such assumption is made.

Applications for new shops require a shop layout plan and the PIC’s practising certificate. Where additional services such as non-sterile compounding, telepharmacy, delivery or e-pharmacy are involved, relevant SOPs, record forms, contractual arrangements and, where applicable, computer system validation documents should also be submitted. HSA arranges an on-site audit after receiving a new application.

— Retail licensing scope: POM, P and specified health products such as oral dental gels.

— HSA audits may examine equipment, facilities for storage/safekeeping/handling, professional reference materials, and systems for retaining supply records and procedures.

— New outlets of pharmacy chains operating similarly to existing licensed outlets may qualify for simplified registration. This arrangement does not apply to outlets proposing to add compounding, delivery, telepharmacy or special supply models.

The import and wholesale of therapeutic products for clinical use require a TPIL and TPWL respectively, and businesses must comply with GDP before licences are issued. If a product registrant outsources import and wholesale activities, including invoicing, the company actually undertaking the contracted activities must still hold the corresponding licences. Full-scope TPIL and TPWL applications may be combined to qualify for a combined fee; restricted-activity TPIL applications are not eligible for this combination.

Imports solely for supply to departing ships or aircraft, solely for export, or for non-clinical use may be handled under a restricted-activity TPIL. HSA states that these activities generally do not require a TPWL. Companies must nevertheless accurately specify their proposed activities in the application and maintain records of receipt, supply or use.

— TPIL/TPWL application documentation: warehouse layout plan, the RP's pharmacist practising certificate where applicable, authorisation letter from the product registrant, list of products intended for wholesale, GDP SOPs and records, site approval letter and outsourcing contracts.

— GDP: HSA generally arranges a site audit after receiving an application. A licence is issued only once requirements are met; risk-based routine or unannounced audits continue after licensing.

— Unregistered therapeutic products for patient use: in addition to TPIL/TPWL, batch approval from the Therapeutic Products Department is required before import.

Local facilities manufacturing or assembling therapeutic products must hold a TPML and comply with GMP before licensing. HSA arranges a pre-approval GMP audit. The SMF should cover the quality system, personnel, premises and equipment, documentation, production, quality control, outsourcing, complaints/recalls and self-inspection, among other matters.

The manufacturing licence must name an RP for production/assembly and an RP for quality operations. HSA requires both to be employed and appointed by the licensee, maintain a GMP-compliant Quality Management System, and possess knowledge and practical experience commensurate with the authorised activities. The verified HSA page does not uniformly require holders of these company roles to possess a particular overseas or local academic qualification. Specific candidates should be confirmed according to the production scope and HSA’s assessment.

— Key documents: SMF, accreditation certificates for contract testing laboratories where applicable, approval letters for manufacturing/storage premises, and details of products, dosage forms, strengths and registration numbers, if any.

— After closure of the GMP audit, if requirements are met, the HSA page states that the licence is approved and issued after 10 working days. This is not the total timeframe from submission to approval.

— A TPML does not exempt the holder from separate licences required for controlled medicines, such as CDML, CDIL, CDWL or CDEL.

A retail pharmacy PIC must be a qualified pharmacist registered with SPC, holding a valid practising certificate and in active practice. The import/wholesale RP is employed and appointed by the business and is responsible for implementing and maintaining the GDP quality system. HSA expressly requires this RP to be a registered pharmacist only when handling POM/P locally or unregistered therapeutic products for patient use. A manufacturing licence must name 2 RPs: one for production/assembly and one for quality operations.

SPC individual registration is a separate procedure. SPC’s published conditions for overseas-trained applicants include recognised qualifications, overseas registration/practice where applicable, practical experience at approved premises in Singapore, employment selection and examinations. The actual route depends on educational background and applicable rules and should be confirmed directly with SPC.

— PIC: named on the pharmacy licence and responsible for controlling and managing the retail pharmacy.

— Import/wholesale RP: responsible for the GDP quality system; must be a registered pharmacist for specified POM/P activities and activities involving unregistered products for patient use.

— Manufacturing RPs: 1 each for production/assembly and quality operations, with relevant knowledge, experience and practical experience.

HSA requires premises information according to the activity, but the verified official pages do not provide a minimum area or fixed room dimensions universally applicable across all sectors. Retail applications must show the dispensing counter, sales area and POM/P storage area. Import/wholesale warehouse plans must show dimensions and areas for receipt, quarantine, release, returns, recalls and dispatch. Manufacturing sites are verified through the SMF and GMP audits.

New retail pharmacies, GDP warehouses and manufacturing sites may all undergo on-site audits. Audits focus on storage, safekeeping, handling, equipment, records and quality systems. Changes involving cold chains, new warehouses or manufacturing processes may require further on-site assessment.

— Retail: pharmacy layout, equipment, professional reference materials and record systems.

— Wholesale/import: GDP storage areas, SOPs, records and applicable site approvals.

— Manufacture: SMF, equipment/quality control, and GMP systems for production and storage.

Applications for pharmacy licences, TPIL/TPWL and TPML are all made through HSA’s PRISM e-service and require a CRIS company account. After documents are submitted, HSA conducts reviews according to the licence type and activities and arranges retail, GDP or GMP audits where applicable. Audit findings must be rectified and closed before the application proceeds to licence issuance.

The activities, product categories, warehouses, outsourcing and additional services determine the documentation required. Retail pharmacies should prepare layout plans, the PIC’s practising certificate and additional-service documents. Importers/wholesalers should prepare GDP documents, warehouse information, product authorisations and RP information. Manufacturers should prepare the SMF, accreditation/premises documents and product and dosage-form information. HSA may request other supporting documents.

— First confirm whether the proposed application is for a TPIL, TPWL, TPML, retail pharmacy licence or a combination of activities.

— Prepare documents in English according to HSA’s published checklists; define both parties’ responsibilities for outsourced activities.

— After submission, cooperate with technical review and applicable on-site audits, rectification and closure procedures.

The following are the principal licensing figures shown on HSA’s fees page as at the verification date. Check them against HSA’s effective fee schedule before payment. HSA’s 10-working-day turnaround standard starts upon completion of technical review or closure of inspection. For applications requiring neither technical review nor inspection, it starts from the application date. In all cases, time taken by the applicant to respond to requests for additional information is excluded.

Pharmacy licences, TPIL, TPWL and TPML are generally valid for 12 months from the approval date, and renewal processing must be completed before expiry. The actual approval date depends on document quality, audits, rectification and HSA requirements; a fixed overall timeframe cannot be promised.

— Retail pharmacy: new application S$560; annual renewal S$560; amendment with on-site assessment S$330, without on-site assessment S$57.

— TPIL/TPWL: full-scope import S$560, wholesale S$560, combined full-scope import and wholesale S$1,000. For restricted TPIL annual or single-consignment fees, refer to HSA’s effective fee schedule respectively (the page lists S$220 and S$111).

— TPML: new applications and renewals cost S$660 to S$3,340 depending on the dosage forms manufactured/packaging activities; variations cost S$57 without an on-site inspection, S$560 with an on-site inspection for packaging-only manufacturers, and S$1,110 with an on-site inspection for other manufacturers.

After licensing, importers and wholesalers must continuously maintain a GDP-compliant Quality Management System (QMS), manufacturers must continuously maintain a GMP system, and retail pharmacies must continue to comply with applicable legislation and licence conditions. HSA schedules routine audits according to risk and compliance levels and may also conduct unannounced audits.

A licence lapses if it is not renewed in time upon expiry, and operations cannot continue under the original licence after it has lapsed; HSA states that a new application must be submitted. GIRO users may opt for automatic renewal, with payment deducted 30 days before expiry; this administrative arrangement does not relieve businesses of their responsibility to verify their licence status and maintain ongoing compliance.

— Quality systems: records, SOPs, receipt/supply, storage, segregation, returns, recalls and applicable outsourced activity management.

— Medicine safety: distributors and product registrants should understand their responsibilities for reporting defects, recalls and serious adverse events.

— Licence maintenance: renew in accordance with HSA's expiry requirements and undergo routine or unannounced audits.

HSA requires amendment applications for changes to company/applicant details, activity scope, premises and other particulars of approved licences. Changes to details such as the company name or address may be processed if the UEN remains unchanged; if the UEN changes, HSA requires a new CRIS account and a new application. This does not support treating a licence as an asset that transfers automatically with a share transaction or a change of entity.

Import/wholesale changes such as adding or relocating a warehouse or introducing cold-chain arrangements may trigger a site inspection; changes to a retail pharmacy's layout, warehouse, remote pharmacy, compounding, delivery or e-pharmacy arrangements may also trigger an inspection. When a manufacturer changes its manufacturing address to one with a different postal code, HSA requires an application for a new TPML; cases such as adding units/floors within the same approved building may be handled through an amendment application under the rules.

— Import/wholesale: switching between full-scope and restricted TPIL requires cancellation of the existing licence before submitting a new application.

— Retail: replacing the PIC generally requires an amendment application and submission of the PIC's practising certificate; HSA may still conduct an inspection where necessary.

— Manufacturing: additions or changes to manufacturing addresses, warehouses, cold-chain arrangements, manufacturing activities, highly sensitising materials, biological products or cytotoxic substances may require a site inspection.

HSA requires therapeutic products to be registered before supply in Singapore; business licences for import, wholesale and manufacturing are a separate layer of requirements. After product registration, changes to safety, efficacy, quality or forensic classification may require an amendment application. An importer that is not the product registrant and has not been authorised by the registrant must still obtain consignment-by-consignment approval and hold a TPIL and TPWL when importing registered products through a special access route.

Import/wholesale of unregistered therapeutic products for patient use requires consignment approval before import, in addition to a TPIL and TPWL; unregistered therapeutic products used solely as clinical research materials for clinical trials are subject to CRM notification rather than TPIL/TPWL requirements. Controlled drugs regulated under the Misuse of Drugs Act require separate corresponding controlled drug licences for import, storage, wholesale, export or manufacture; a TP licence or pharmacy licence does not automatically cover these activities.

— Special consignments of registered products: each application is limited to one consignment under one product registration number; the product must still be registered in Singapore at the time of approval.

— Controlled drugs: CDIL, CDWL, CDEL and CDML must be obtained separately according to the activity. HSA requires licence holders storing/wholesaling or manufacturing controlled drugs to be SPC-registered pharmacists.

— Controlled drug imports: before importing therapeutic products, the relevant therapeutic product dealer's licence or approval must also be held; subsequent wholesale after import requires a separate CDWL.